Company: SION
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-101830
Chunk: 32

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 32
---
 served as our Chief Legal Officer since April 2025. Previously, Ms. Fitzpatrick served as our Senior Vice President and General Counsel from June 2024 to March 2025. Prior to joining Sionna, Ms. Fitzpatrick served as Vice President, Corporate Counsel at Sage Therapeutics, Inc. (NASDAQ: SAGE) from July 2018 to June 2024. Previously, Ms. Fitzpatrick served in multiple roles at Aegerion Pharmaceuticals, Inc. from January 2014 to July 2018, including most recently as Vice President, Corporate Counsel from January 2016 to July 2018. Ms. Fitzpatrick earned a J.D. from the University of Virginia School of Law and a B.A. from Middlebury College. The principal occupation and employment during the past five years of each of our executive officers was carried on, in each case except as specifically identified in this proxy statement, with a corporation or organization that is not a parent, subsidiary or other affiliate of us. There is no arrangement or understanding between any of our executive officers and any other person or persons pursuant to which he or she was or is to be selected as an executive officer. There are no material legal proceedings to which any of our directors, executive officers, or affiliates is a party adverse to us or our subsidiary or in which any such person has a material interest adverse to us or our subsidiary. Director Compensation The table below shows all compensation awarded to, earned by or paid to each person who served as a non-employeedirector during 2024. Non-employeedirectors Bruce Booth, Lucian Iancovici, H. Edward Fleming, Jr., Joshua Resnick, and Peter A. Thompson did not receive cash or equity compensation from us for their services as directors during 2024 due to their affiliation with Atlas Venture, TPG Growth, Enavate Sciences, RA Capital Management, L.P. and OrbiMed Advisors LLC, respectively. Our former non-employeedirector, Adam Rosenberg, also did not receive cash or equity compensation from us for his services as a director due to 22

his former affiliation with RA Capital Management, L.P. and his former position as our chief executive officer prior to 2023. Other than as set forth in the table and described more fully below, we did not pay any compensation, make any equity awards or non-equityawards to, or pay any other compensation to any of the non-employeemembers of our board of directors in